HK Stock Market Move | REMEGEN (09995) rose more than 4%. Vedolizumab was approved for its fourth indication, adding a new indication for breast cancer.

REMEGEN (09995) surged by more than 4%, as of the time of writing, it increased by 3.82%, reaching 90.6 Hong Kong dollars, with a turnover of 67.6447 million Hong Kong dollars. On the news front, REMEGEN announced that its independently developed injection vedolizumab monoclonal antibody (trade name: Aida Xi) has been approved by the National Medical Products Administration for a new indication for the treatment of specific populations with breast cancer. This is the fourth indication approved for this drug in China, further expanding its clinical application scope. As one of REMEGEN's core products, the expansion of vedolizumab monoclonal antibody indications will further enrich the company's product portfolio and enhance its core competitiveness. It is reported that this drug has been successfully included in the second category list through national medical insurance negotiations in 2024, significantly reducing the out-of-pocket ratio for patients and driving a significant increase in terminal prescription volume, laying the foundation for the market promotion of the new indication.